NASDAQ · AMPH
Healthcare · Drug Manufacturers - Specialty & Generic
$23.64
Up+$0.50 (+2.10%)
Updated Sep 16, 2026, 4:04 PM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
AMPH closed at $23.64 after 20 trading sessions, up 10.78% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $23.75 | $23.938 | $23.56 | $23.64 | 354.42K |
| Sep 14, 2026 | $23.84 | $24.28 | $23.555 | $23.91 | 474.88K |
| Sep 11, 2026 | $23.65 | $23.80 | $23.24 | $23.78 | 410.95K |
| Sep 10, 2026 | $23.00 | $23.69 | $22.755 | $23.54 | 514.99K |
| Sep 9, 2026 | $22.84 | $23.07 | $22.5748 | $23.04 | 351.6K |
| Sep 8, 2026 | $22.82 | $23.14 | $22.30 | $22.93 | 460.02K |
| Sep 4, 2026 | $23.47 | $23.74 | $23.07 | $23.18 | 650.13K |
| Sep 3, 2026 | $23.875 | $23.92 | $23.04 | $23.84 | 469.75K |
| Sep 2, 2026 | $23.05 | $23.83 | $23.0275 | $23.74 | 456.78K |
| Sep 1, 2026 | $22.59 | $23.05 | $22.59 | $22.96 | 550.98K |
| Aug 31, 2026 | $21.86 | $22.65 | $21.52 | $22.53 | 274.03K |
| Aug 28, 2026 | $21.88 | $22.15 | $21.69 | $22.01 | 224.53K |
| Aug 27, 2026 | $21.69 | $21.97 | $21.625 | $21.88 | 259.79K |
| Aug 26, 2026 | $21.86 | $22.435 | $21.715 | $22.02 | 395.61K |
| Aug 25, 2026 | $21.50 | $22.0699 | $21.405 | $21.98 | 283.77K |
| Aug 24, 2026 | $21.60 | $21.81 | $21.2601 | $21.52 | 210.26K |
| Aug 21, 2026 | $21.64 | $22.20 | $21.44 | $21.60 | 376.56K |
| Aug 20, 2026 | $21.38 | $21.76 | $21.24 | $21.68 | 338.7K |
| Aug 19, 2026 | $21.64 | $21.99 | $21.145 | $21.74 | 410.77K |
| Aug 18, 2026 | $21.11 | $21.59 | $21.075 | $21.34 | 411.88K |
The latest Smart Investors Daily articles mentioning AMPH.
AMPH research
Company profile and research snapshot.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 18, 2026 | Barclays | Equal-Weight | — |
| Aug 7, 2026 | Wells Fargo | Equal-Weight | — |
| Aug 7, 2026 | Piper Sandler | Neutral | — |
| Jun 29, 2026 | B of A Securities | Underperform | — |
| Jun 3, 2026 | Barclays | Equal-Weight | — |
No generated briefing is available yet.
Benzinga · Mar 6, 2026
Entry into Material Definitive Agreement and Amendment of a Material Definitive Agreement. Supply Agreement. On March 3, 2026, (the "Effective Date"), Amphastar Nanjing Pharmaceuticals, Inc. ("ANP"), the
SeekingAlpha · Feb 28, 2026
Benzinga · Feb 27, 2026
Wells Fargo analyst Benjamin Burnett maintains Amphastar Pharma (NASDAQ:AMPH) with a Overweight and lowers the price target from $34 to $30.
Benzinga · Feb 27, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AMPH.
